Regeneron Pharmaceuticals Inc. buy jde
Start price
16.12.15
/
50%
€513.48
Target price
16.06.16
€547.00
Performance (%)
-36.59%
End price
16.06.16
€325.62
Summary
This prediction ended on 16.06.16 with a price of €325.62. The BUY prediction by jde for Regeneron Pharmaceuticals Inc. performed very badly with a performance of -36.59%. jde has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 2.860% | 2.860% | 22.809% | -13.100% |
| iShares Core DAX® | 4,57 % | 4,14 % | 7,35 % | 57,58 % |
| iShares Nasdaq 100 | 1,83 % | -1,64 % | 33,64 % | 88,08 % |
| iShares Nikkei 225® | -0,29 % | 2,47 % | 60,45 % | 76,67 % |
| iShares S&P 500 | 2,23 % | 0,71 % | 24,13 % | 66,11 % |
Comments by jde for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Gute Bilanz, schönes Potential
(Laufzeit überschritten)